Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9043462 | 0.86 | FFAR3 (0.59) | FFAR3 | |
| SCHEMBL1744112 | 0.81 | — | — | |
| SCHEMBL4486583 | 0.78 | NPSR1 (0.33) | — | |
| SCHEMBL3519272 | 0.76 | FFAR3 (0.50) | FFAR3 | |
| SCHEMBL24180314 | 0.74 | FFAR3 (0.48) | FFAR3 | |
| SCHEMBL17131051 | 0.74 | FFAR3 (0.48) | FFAR3 | |
| SCHEMBL15981231 | 0.73 | FFAR3 (0.35) | FFAR3 | |
| SCHEMBL2311457 | 0.70 | FFAR3 (0.62) | FFAR3 | |
| SCHEMBL4470839 | 0.69 | — | — | |
| SCHEMBL5729131 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7390803-B2 | Tetrahydropyranyl cyclopentyl benzylamide modulators of chemokine receptor activity | MERCK & CO., INC. (US) | 2008-06-24 | — | — | US | disclosed |
| EP-1558243-A4 | TETRAHYDROPYRANYL CYCLOPENTYL BENZYLAMIDE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO INC (US) | 2006-11-02 | — | — | EP | disclosed |
| EP-1318811-B1 | CYCLOPENTYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO INC (US) | 2006-08-30 | — | — | EP | disclosed |
| US-20060116421-A1 | Tetrahydropyranyl cyclopentyl benzylamide modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. | 2006-06-01 | — | — | US | disclosed |
| EP-1558243-A2 | TETRAHYDROPYRANYL CYCLOPENTYL BENZYLAMIDE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Merck & Co., Inc. (US) | 2005-08-03 | — | — | EP | disclosed |
| EP-1318811-A4 | CYCLOPENTYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO INC (US) | 2004-07-14 | — | — | EP | disclosed |
| WO-2004041161-A2 | TETRAHYDROPYRANYL CYCLOPENTYL BENZYLAMIDE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2004-05-21 | — | — | WO | disclosed |
| EP-1318811-A1 | CYCLOPENTYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Merck & Co., Inc. (US) | 2003-06-18 | — | — | EP | disclosed |
| US-6545023-B2 | For treating rheumatoid arthritis; for examle, 1-(4-(4-fluorophenyl)piperidin-1-yl),3-(2-methoxy-4 -chlorobenzylaminocarbonyl),3-isopropyl-cyclopentane | MERCK & CO., INC. | 2003-04-08 | — | — | US | disclosed |
| US-20020049222-A1 | Cyclopentyl modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. | 2002-04-25 | — | — | US | disclosed |
| WO-2002013824-A1 | CYCLOPENTYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2002-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049222-A1 | Cyclopentyl modulators of chemokine receptor activity | CCR1, CCRL2, CCR5 | FFAR3 162/4885 |
| US-20060116421-A1 | Tetrahydropyranyl cyclopentyl benzylamide modulators of chemokine receptor activity | CCR2, CCR1, CCR9 | FFAR3 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.